Analysts’ Weekly Ratings Changes for Galapagos (GLPG)

Galapagos (NASDAQ: GLPG) has recently received a number of price target changes and ratings updates:

• 11/7/2025 – Galapagos had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $32.00. They now have a “sector perform” rating on the stock.
• 10/22/2025 – Galapagos had its price target raised by analysts at Royal Bank Of Canada from $27.00 to $28.00. They now have a “sector perform” rating on the stock.
• 10/22/2025 – Galapagos was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 10/21/2025 – Galapagos was given a new $40.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 10/8/2025 – Galapagos had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Galapagos had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.